Early MS treatment

International MS Journal

Volumn 14, Issue 1, 2007, Pages 5-10

  Tintore M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Clinically isolated syndromes; Disease modifying agents; Early treatment; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EARLY DIAGNOSIS; HUMANS; MULTIPLE SCLEROSIS;

EID: 34250328850     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
2. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846.
3. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399.
4. Bruck W, Schmied M, Suchanek G, Bruck Y, Breitschopf H, Poser S et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35: 65-73.
5. Bruck W, Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 2005; 18: 221-224.
6. Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 2000; 21: 1034-1038.
7. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433-437.
8. Weinshenker BG, Bass GP, Rice J, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. I Clinical course and disability. Brain 1989; 112: 133-146
9. Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Wegand SD, NoseworthyJH et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; 62: 51-59.
10. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-782.
11. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993; 116: 135-146.
12. O'Riordan JI, Thompson AJ, Kingsley DPE, MacManus DG, Kendall BE, Rudge P et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10 year follow-up. Brain 1998; 121: 495-503.
13. Brex PA, Ciccarelli O, Jonathon I, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164.
14. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-2069.
15. Tintore M, Rovira A, Martinez MJ, Rio J, Diaz-Villoslada P, Brieva L et al. Isolated demyelinating syndromes: comparison of different MRI criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000; 21: 702-706.
16. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-972.
17. Beck RW, Smith CH, Gal RL, Xing D, Bhatti MT, Brodsky MC et al. Optic Neuritis Study Group. Neurological impairment 10 years after optic neuritis. Arch Neurol 2004; 61: 1386-1389.
18. Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005; 57: 210-215.
19. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349: 139-145.
20. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scl 2005; 11: 492-494.
21. Pelayo R, Tintore M, Montalban X, Rovira A, Espejo C, Reindl M et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007; 356: 426-428.
22. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356: 371-378.
23. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon-beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
24. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001; 357: 1576-1582.
25. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.
26. Polman CH, Kappos L, Freedman MS et al. for the BENEFIT Study Group. Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Subgroup Analyses. Neurology 2006; 66 (Suppl 2): A61.
27. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684.
28. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1463-1464.
29. Río J, Tintore M, Nos C, Tellez N, Galan I, Montalban X. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 2005; 252: 795-800.
30. Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo MJ et al. Factors related with treatment adherence to IFNbeta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 1-4.
31. Roach ES. Early multiple sclerosis: to treat or not to treat? Arch Neurol 2006; 63: 619.
32. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006; 63: 614-619.
33. Pittock SJ, Weinshenker BG, Noseworthy JH, Lucchinetti CF, Keegan M, Wingerchuk DM et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 2006; 63: 611-614.